JAZZ
Price
$136.01
Change
-$0.64 (-0.47%)
Updated
Feb 21 closing price
Capitalization
8.22B
2 days until earnings call
SRPT
Price
$106.28
Change
-$2.13 (-1.96%)
Updated
Feb 21 closing price
Capitalization
10.15B
3 days until earnings call
Ad is loading...

JAZZ vs SRPT

Header iconJAZZ vs SRPT Comparison
Open Charts JAZZ vs SRPTBanner chart's image
Jazz Pharmaceuticals
Price$136.01
Change-$0.64 (-0.47%)
Volume$575.55K
Capitalization8.22B
Sarepta Therapeutics
Price$106.28
Change-$2.13 (-1.96%)
Volume$709.35K
Capitalization10.15B
JAZZ vs SRPT Comparison Chart
Loading...
JAZZ
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
SRPT
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
JAZZ vs. SRPT commentary
Feb 23, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is JAZZ is a Hold and SRPT is a Hold.

Ad is loading...
COMPARISON
Comparison
Feb 23, 2025
Stock price -- (JAZZ: $136.01 vs. SRPT: $106.28)
Brand notoriety: JAZZ: Not notable vs. SRPT: Notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: JAZZ: 92% vs. SRPT: 90%
Market capitalization -- JAZZ: $8.22B vs. SRPT: $10.15B
JAZZ [@Biotechnology] is valued at $8.22B. SRPT’s [@Biotechnology] market capitalization is $10.15B. The market cap for tickers in the [@Biotechnology] industry ranges from $393.7B to $0. The average market capitalization across the [@Biotechnology] industry is $2.51B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

JAZZ’s FA Score shows that 0 FA rating(s) are green whileSRPT’s FA Score has 0 green FA rating(s).

  • JAZZ’s FA Score: 0 green, 5 red.
  • SRPT’s FA Score: 0 green, 5 red.
According to our system of comparison, JAZZ is a better buy in the long-term than SRPT.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

JAZZ’s TA Score shows that 6 TA indicator(s) are bullish while SRPT’s TA Score has 4 bullish TA indicator(s).

  • JAZZ’s TA Score: 6 bullish, 4 bearish.
  • SRPT’s TA Score: 4 bullish, 5 bearish.
According to our system of comparison, JAZZ is a better buy in the short-term than SRPT.

Price Growth

JAZZ (@Biotechnology) experienced а +1.53% price change this week, while SRPT (@Biotechnology) price change was -1.55% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -1.71%. For the same industry, the average monthly price growth was -2.01%, and the average quarterly price growth was +0.86%.

Reported Earning Dates

JAZZ is expected to report earnings on Apr 30, 2025.

SRPT is expected to report earnings on Apr 30, 2025.

Industries' Descriptions

@Biotechnology (-1.71% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
SRPT($10.2B) has a higher market cap than JAZZ($8.22B). SRPT has higher P/E ratio than JAZZ: SRPT (69.01) vs JAZZ (19.26). JAZZ YTD gains are higher at: 10.443 vs. SRPT (-12.591). JAZZ has higher annual earnings (EBITDA): 1.31B vs. SRPT (187M). JAZZ has more cash in the bank: 2.62B vs. SRPT (1.2B). SRPT has less debt than JAZZ: SRPT (1.4B) vs JAZZ (6.2B). JAZZ has higher revenues than SRPT: JAZZ (3.99B) vs SRPT (1.64B).
JAZZSRPTJAZZ / SRPT
Capitalization8.22B10.2B81%
EBITDA1.31B187M699%
Gain YTD10.443-12.591-83%
P/E Ratio19.2669.0128%
Revenue3.99B1.64B243%
Total Cash2.62B1.2B219%
Total Debt6.2B1.4B444%
FUNDAMENTALS RATINGS
JAZZ vs SRPT: Fundamental Ratings
JAZZ
SRPT
OUTLOOK RATING
1..100
3679
VALUATION
overvalued / fair valued / undervalued
1..100
65
Fair valued
81
Overvalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
6160
PRICE GROWTH RATING
1..100
4380
P/E GROWTH RATING
1..100
10099
SEASONALITY SCORE
1..100
n/an/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

JAZZ's Valuation (65) in the Pharmaceuticals Other industry is in the same range as SRPT (81) in the Biotechnology industry. This means that JAZZ’s stock grew similarly to SRPT’s over the last 12 months.

JAZZ's Profit vs Risk Rating (100) in the Pharmaceuticals Other industry is in the same range as SRPT (100) in the Biotechnology industry. This means that JAZZ’s stock grew similarly to SRPT’s over the last 12 months.

SRPT's SMR Rating (60) in the Biotechnology industry is in the same range as JAZZ (61) in the Pharmaceuticals Other industry. This means that SRPT’s stock grew similarly to JAZZ’s over the last 12 months.

JAZZ's Price Growth Rating (43) in the Pharmaceuticals Other industry is somewhat better than the same rating for SRPT (80) in the Biotechnology industry. This means that JAZZ’s stock grew somewhat faster than SRPT’s over the last 12 months.

SRPT's P/E Growth Rating (99) in the Biotechnology industry is in the same range as JAZZ (100) in the Pharmaceuticals Other industry. This means that SRPT’s stock grew similarly to JAZZ’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
JAZZSRPT
RSI
ODDS (%)
Bearish Trend 3 days ago
63%
Bullish Trend 3 days ago
74%
Stochastic
ODDS (%)
Bearish Trend 3 days ago
65%
Bullish Trend 3 days ago
81%
Momentum
ODDS (%)
Bullish Trend 3 days ago
63%
Bearish Trend 3 days ago
78%
MACD
ODDS (%)
Bullish Trend 3 days ago
63%
Bearish Trend 3 days ago
75%
TrendWeek
ODDS (%)
Bearish Trend 3 days ago
57%
Bearish Trend 3 days ago
74%
TrendMonth
ODDS (%)
Bullish Trend 3 days ago
68%
Bearish Trend 3 days ago
72%
Advances
ODDS (%)
Bullish Trend 11 days ago
63%
Bullish Trend 4 days ago
75%
Declines
ODDS (%)
Bearish Trend 18 days ago
58%
Bearish Trend 6 days ago
76%
BollingerBands
ODDS (%)
Bearish Trend 3 days ago
59%
Bullish Trend 3 days ago
84%
Aroon
ODDS (%)
Bullish Trend 3 days ago
68%
Bearish Trend 3 days ago
63%
View a ticker or compare two or three
Ad is loading...
JAZZ
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
SRPT
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
IAUM29.28-0.03
-0.10%
iShares® Gold Trust Micro
VOE164.84-1.85
-1.11%
Vanguard Mid-Cap Value ETF
GOAU21.60-0.77
-3.46%
US Global GO GOLD and Prec Mtl Mnrs ETF
TIME26.21-0.97
-3.58%
Clockwise Core Equity & Innovation ETF
ARKX19.74-0.74
-3.61%
ARK Space Exploration & Innovation ETF

JAZZ and

Correlation & Price change

A.I.dvisor indicates that over the last year, JAZZ has been loosely correlated with AMLX. These tickers have moved in lockstep 43% of the time. This A.I.-generated data suggests there is some statistical probability that if JAZZ jumps, then AMLX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To JAZZ
1D Price
Change %
JAZZ100%
-0.47%
AMLX - JAZZ
43%
Loosely correlated
-6.25%
SRPT - JAZZ
35%
Loosely correlated
-1.96%
AXON - JAZZ
34%
Loosely correlated
-5.28%
VCYT - JAZZ
34%
Loosely correlated
-4.56%
INO - JAZZ
33%
Poorly correlated
+0.90%
More